» Articles » PMID: 23630258

Self-assembled, Aptamer-tethered DNA Nanotrains for Targeted Transport of Molecular Drugs in Cancer Theranostics

Overview
Specialty Science
Date 2013 May 1
PMID 23630258
Citations 125
Authors
Affiliations
Soon will be listed here.
Abstract

Nanotechnology has allowed the construction of various nanostructures for applications, including biomedicine. However, a simple target-specific, economical, and biocompatible drug delivery platform with high maximum tolerated doses is still in demand. Here, we report aptamer-tethered DNA nanotrains (aptNTrs) as carriers for targeted drug transport in cancer therapy. Long aptNTrs were self-assembled from only two short DNA upon initiation by modified aptamers, which worked like locomotives guiding nanotrains toward target cancer cells. Meanwhile, tandem "boxcars" served as carriers with high payload capacity of drugs that were transported to target cells and induced selective cytotoxicity. aptNTrs enhanced maximum tolerated dose in nontarget cells. Potent antitumor efficacy and reduced side effects of drugs delivered by biocompatible aptNTrs were demonstrated in a mouse xenograft tumor model. Moreover, fluorophores on nanotrains and drug fluorescence dequenching upon release allowed intracellular signaling of nanotrains and drugs. These results make aptNTrs a promising targeted drug transport platform for cancer theranostics.

Citing Articles

Progressive cancer targeting by programmable aptamer-tethered nanostructures.

Mohammadi F, Zahraee H, Zibadi F, Khoshbin Z, Ramezani M, Alibolandi M MedComm (2020). 2024; 5(11):e775.

PMID: 39434968 PMC: 11491555. DOI: 10.1002/mco2.775.


RNA nanostructures for targeted drug delivery and imaging.

Teodori L, Omer M, Kjems J RNA Biol. 2024; 21(1):1-19.

PMID: 38555519 PMC: 10984137. DOI: 10.1080/15476286.2024.2328440.


MicroRNA-29c-tetrahedral framework nucleic acids: Towards osteogenic differentiation of mesenchymal stem cells and bone regeneration in critical-sized calvarial defects.

Sun J, Chen X, Lin Y, Cai X Cell Prolif. 2024; 57(7):e13624.

PMID: 38414296 PMC: 11216942. DOI: 10.1111/cpr.13624.


Engineered nanodrug targeting oxidative stress for treatment of acute kidney injury.

Li L, Shen Y, Tang Z, Yang Y, Fu Z, Ni D Exploration (Beijing). 2024; 3(6):20220148.

PMID: 38264689 PMC: 10742205. DOI: 10.1002/EXP.20220148.


Aptamer-engineered (nano)materials for theranostic applications.

Rabiee N, Chen S, Ahmadi S, Veedu R Theranostics. 2023; 13(15):5183-5206.

PMID: 37908725 PMC: 10614690. DOI: 10.7150/thno.85419.


References
1.
MacKay J, Chen M, McDaniel J, Liu W, Simnick A, Chilkoti A . Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater. 2009; 8(12):993-9. PMC: 2862348. DOI: 10.1038/nmat2569. View

2.
Tan W, Wang H, Chen Y, Zhang X, Zhu H, Yang C . Molecular aptamers for drug delivery. Trends Biotechnol. 2011; 29(12):634-40. PMC: 3218254. DOI: 10.1016/j.tibtech.2011.06.009. View

3.
Huang Y, Shangguan D, Liu H, Phillips J, Zhang X, Chen Y . Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 2009; 10(5):862-8. PMC: 2992821. DOI: 10.1002/cbic.200800805. View

4.
Luo D, Saltzman W . Synthetic DNA delivery systems. Nat Biotechnol. 2000; 18(1):33-7. DOI: 10.1038/71889. View

5.
Ireson C, Kelland L . Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006; 5(12):2957-62. DOI: 10.1158/1535-7163.MCT-06-0172. View